Author Archives for Adeline Chauvigné

New member | Croda – Smart Science to Improve Lives

1 July 2025

Established in 1925, Croda is the name behind high performance ingredients and technologies in some of the world’s biggest and... View Article

New member | Biowest – The serum specialist

1 July 2025

Based in Nuaillé (Cholet), Biowest was founded in 1987. The company launched its activity by processing and distributing animal sera... View Article

Phase 3 Clinical Trial of Tedopi®: OSE Immunotherapeutics Announces Positive Top-Line Results for Step-1 of its trial ‘Atalante 1’ in Non-Small Cell Lung Cancer

1 July 2025

• Step-1 primary endpoint met: 12-month survival rate in Tedopi® treated patients; • Complete analysis of Step-1 results and further... View Article

OSE Immunotherapeutics and Servier Amend the Global Licensing Option Agreement for IL-7R Antagonist OSE-127 in Autoimmune Diseases

1 July 2025

Under this amendment, OSE Immunotherapeutics will receive a €5 million milestone payment at the start of the Sjögren’s Phase 2... View Article

GRAFTYS ADDS A NEW DISTRIBUTION PARTNERSHIP IN THE US TERRITORY

1 July 2025

  GRAFTYS SA (“Graftys”), a global leader in resorbable bone cements, today announces a new distribution agreement for its bestselling... View Article

NEW MEMBER | WELIOM

1 July 2025

ASSESS, ADVISE, STEER WELIOM is emerging as a partner in the reconfiguration of healthcare institutions, deploying healthcare stakeholders, recognised experts... View Article

NEW MEMBER | NUCLEOPOLIS

1 July 2025

NUCLEOPOLIS, THE NORMANDIE ENERGIES NUCLEAR CLUSTER Nucleopolis is the Normandie Énergies nuclear cluster, a major player in the Normandy energy... View Article

NEW MEMBER | GUTY

1 July 2025

THE SMART ASSISTANT PROVIDING CARE AND SUPPORT SERVICES FOR GASTROINTESTINAL DISORDERS AND DIGESTIVE DISEASES Guty is the leading smart solution... View Article

NEW MEMBER | ADWST

1 July 2025

THERAPEUTIC WATER DEVELOPMENT NATARYS was created in 2007 based on the strongly held belief that providing people with access to... View Article

ABOLERIS PHARMA – CONTROLLING AUTOIMMUNE DISEASES AND TRANSPLANT REJECTIONS

1 July 2025

ABOLERIS PHARMA, AN EMERGING COMPANY IN THE FIELD OF IMMUNOTHERAPY RESEARCH ESTABLISHED ON 28th NOVEMBER 2019, DEVELOPS PROPRIETARY MOLECULES THAT... View Article